![Quiver Logo](/static/img/logo-icon.png)
![VRDN logo](https://quiver-logos.s3.us-east-2.amazonaws.com/vrdn.png)
Viridian Therapeutics, Inc. Common Stock
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view VRDN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of VRDN by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by VRDN's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to VRDN
Recent picks made for VRDN stock on CNBC
ETFs with the largest estimated holdings in VRDN
Flights by private jets registered to VRDN
![Quiver Logo](/static/img/logo-icon.png)